Ticker
ADCT

Price
3.62
Stock movement up
+0.14 (4.02%)
Company name
Adc Therapeutics SA
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
278.05M
Ent value
266.40M
Price/Sales
3.46
Price/Book
1.71
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-83.85%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2022-12-05

DIVIDENDS

ADCT does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales3.46
Price to Book1.71
EV to Sales3.31

FINANCIALS

Per share

Loading...
Per share data
Current share count76.81M
EPS (TTM)-2.54
FCF per share (TTM)-2.85

Income statement

Loading...
Income statement data
Revenue (TTM)80.42M
Gross profit (TTM)78.49M
Operating income (TTM)-231.42M
Net income (TTM)-195.16M
EPS (TTM)-2.54
EPS (1y forward)-3.23

Margins

Loading...
Margins data
Gross margin (TTM)97.61%
Operating margin (TTM)-287.78%
Profit margin (TTM)-242.69%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash430.87M
Net receivables26.75M
Total current assets487.71M
Goodwill0.00
Intangible assets13.85M
Property, plant and equipment0.00
Total assets581.89M
Accounts payable16.45M
Short/Current long term debt0.00
Total current liabilities70.77M
Total liabilities419.22M
Shareholder's equity162.67M
Net tangible assets149.53M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-212.11M
Capital expenditures (TTM)6.72M
Free cash flow (TTM)-218.84M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-119.98%
Return on Assets-33.54%
Return on Invested Capital-71.44%
Cash Return on Invested Capital-80.11%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open3.48
Daily high3.64
Daily low3.33
Daily Volume557K
All-time high51.05
1y analyst estimate27.50
Beta1.29
EPS (TTM)-2.54
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
ADCTS&P500
Current price drop from All-time high-92.91%-14.82%
Highest price drop-93.38%-56.47%
Date of highest drop29 Nov 20229 Mar 2009
Avg drop from high-54.12%-11.46%
Avg time to new high40 days13 days
Max time to new high611 days1805 days
COMPANY DETAILS
ADCT (Adc Therapeutics SA) company logo
Marketcap
278.05M
Marketcap category
Small-cap
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Employees
312
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
GSK and Roche have pulled drugs approved on an accelerated basis, while other drugmakers win speedy approvals only after starting confirmatory studies.
December 5, 2022
BEIJING, November 28, 2022--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics...
November 28, 2022
As every investor would know, you don't hit a homerun every time you swing. But it's not unreasonable to try to avoid...
November 16, 2022
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of -27.45% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc...
November 8, 2022
LAUSANNE, Switzerland, November 08, 2022--ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the third quarter ended September 30, 2022 and provided business updates.
November 8, 2022
LAUSANNE, Switzerland, November 07, 2022--ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healt...
November 7, 2022
Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt...
November 4, 2022
LAUSANNE, Switzerland, November 03, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on several of its antibody drug conjugates (ADCs), including ZYNLONTA® (loncastuximab tesirine-lpyl...
November 3, 2022
– Companies to Leverage Lead Product Candidate from IGM’s Proprietary IgM Antibody Platform with ZYNLONTA® for Novel Combination Therapy in Relapsed/Refractory B Cell NHL – – Phase 1 Trial Expected to...
November 2, 2022
LAUSANNE, Switzerland, November 01, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Kristen Harrington-Smith as Chief Commercial Officer, effective November 17, 2022. The Com...
November 1, 2022
Next page